Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Geneuro SA
GNROGeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family; treats type 1 diabetes; and treats chronic inflammatory demyelinating polyneuropathy. It also developing GNK301. In addition, It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic centers to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland. Address: 3 chemin du PrE-Fleuri, Plan-les-Ouates, Switzerland, 1228
Analytics
Objectif de Cours de WallStreet
6.59 EURRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés GNRO
Analyse des dividendes GNRO
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes GNRO
Valorisation des titres GNRO
financières GNRO
Résultats | 2019 | Dynamique |